Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

BACKGROUND: Patient-reported outcomes (PROs) might detect more toxic effects of radiotherapy than do clinician-reported outcomes. We did a quality of life (QoL) substudy to assess PROs up to 24 months after conventionally fractionated or hypofractionated radiotherapy in the Conventional or Hypofract...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilkins, Anna, Mossop, Helen, Syndikus, Isabel, Khoo, Vincent, Bloomfield, David, Parker, Chris, Logue, John, Scrase, Christopher, Patterson, Helen, Birtle, Alison, Staffurth, John, Malik, Zafar, Panades, Miguel, Eswar, Chinnamani, Graham, John, Russell, Martin, Kirkbride, Peter, O'Sullivan, Joe M, Gao, Annie, Cruickshank, Clare, Griffin, Clare, Dearnaley, David, Hall, Emma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2015
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4664817/
https://www.ncbi.nlm.nih.gov/pubmed/26522334
http://dx.doi.org/10.1016/S1470-2045(15)00280-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4664817/
https://www.ncbi.nlm.nih.gov/pubmed/26522334
http://dx.doi.org/10.1016/S1470-2045(15)00280-6

Ejemplares similares